(Q26771611)

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Isomerization in the CDR2 of a monoclonal antibody: Binding analysis and factors that influence the isomerization rate

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Real-time product attribute control to manufacture antibodies with defined N-linked glycan levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Antibody structure, instability, and formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Heterogeneity of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Reversed-phase ion-pairing liquid chromatography/ion trap mass spectrometry for the analysis of negatively charged, derivatized glycans

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Glutamine deamidation of a recombinant monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Capillary electrophoresis/electrospray ion trap mass spectrometry for the analysis of negatively charged derivatized and underivatized glycans

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Nanoscale reversed-phase liquid chromatography-mass spectrometry of permethylated N-glycans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

High-throughput immunoglobulin G N-glycan characterization using rapid resolution reverse-phase chromatography tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Online nanoliquid chromatography–mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Comparison of hydrophilic-interaction, reversed-phase and porous graphitic carbon chromatography for glycan analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Pharmacological significance of glycosylation in therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

The mannose receptor: linking homeostasis and immunity through sugar recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Naturally occurring glycan forms of human immunoglobulins G1 and G2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Recognition of immunoglobulins by Fcgamma receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Identification of multiple sources of charge heterogeneity in a recombinant antibody.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Isoaspartate in peptides and proteins: formation, significance, and analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Normal-phase nanoscale liquid chromatography-mass spectrometry of underivatized oligosaccharides at low-femtomole sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

In vivo deamidation characterization of monoclonal antibody by LC/MS/MS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Glycosylation as a strategy to improve antibody-based therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

FcRn: the neonatal Fc receptor comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Human IgG2 antibodies display disulfide-mediated structural isoforms

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Structural and functional characterization of disulfide isoforms of the human IgG2 subclass

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Post-translational modifications differentially affect IgG1 conformation and receptor binding.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Capillary electrophoresis-electrospray ionization mass spectrometry for rapid and sensitive N-glycan analysis of glycoproteins as 9-fluorenylmethyl derivatives

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

The effect of Fc glycan forms on human IgG2 antibody clearance in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Rates and impact of human antibody glycation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

New high-performance liquid chromatography assay for glycosyltransferases based on derivatization with anthranilic acid and fluorescence detection

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Mannose receptor-mediated regulation of serum glycoprotein homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Carbohydrate-Specific Receptors of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

The asialoglycoprotein receptor: relationships between structure, function, and expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Impact of glycation on antibody clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Impact of Glycosylation on Effector Functions of Therapeutic IgG

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Marketed therapeutic antibodies compendium

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Increased serum clearance of oligomannose species present on a human IgG1 molecule

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

The impact of glycosylation on monoclonal antibody conformation and stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPB.2016.01.005

7 January 2021

10.1016/J.EJPB.2016.01.005

Identifiers

DOI

0 references

Fatcat ID

release_ncigv3uixjemfotpjgslpvxtdy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ncigv3uixjemfotpjgslpvxtdy

24 November 2022